Bill Anderson

William N. (Bill) Anderson serves as Chairman of the Board of Management (CEO) of Bayer AG since June 1, 2023, leading the German pharmaceutical and life sciences giant through one of its most significant transformations in its 160-year history. Born August 23, 1966, in Ohio, Texas, Anderson represents a new era of American leadership at the iconic German company, becoming the first American CEO in Bayer's long history. With a distinguished educational foundation including a Bachelor of Science in Chemical Engineering from the University of Texas at Austin and dual Master of Science degrees in Chemical Engineering and Management from the Massachusetts Institute of Technology (MIT), including MIT's prestigious Sloan School of Management, Anderson combines deep technical expertise with strategic business acumen. His academic excellence laid the groundwork for a remarkable career spanning over three decades in the pharmaceutical and biotechnology industries. Anderson's career trajectory exemplifies the modern pharmaceutical executive, having held leadership positions across multiple global organizations including Ethyl Corporation, Biogen, Genentech, and Roche Pharmaceuticals. His tenure as CEO of Roche Pharmaceuticals (2019-2022) was marked by successful transformation initiatives, new product launches, significant revenue growth, and enhanced organizational productivity across the world's largest biotechnology company. As CEO of Bayer, Anderson has implemented his revolutionary "Dynamic Shared Ownership" (DSO) transformation strategy, fundamentally reshaping the company's organizational structure by eliminating bureaucratic layers, empowering self-directed teams, and accelerating decision-making processes. His leadership philosophy emphasizes agility, innovation, and operational excellence, with ambitious goals to restore Bayer's financial performance and position the company for sustained growth in pharmaceuticals, crop science, and consumer health. Under his guidance, Bayer is undergoing a comprehensive cultural and operational transformation, moving from traditional hierarchical structures to agile, self-organizing teams focused on delivering value to patients and customers worldwide.